Moderna Prices Upsized $2.6B Offering of Convertible Senior Notes (MRNA:NASDAQ)

Moderna prices upsized $2.6B offering of convertible senior notes (MRNA:NASDAQ)

Moderna prices $2.6B 0% convertible notes due 2032, upsized deal with capped call and 47.5% conversion premium—get key terms and impact now.

Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes

Proceeds to be utilized for general corporate purposes which may include the flexibility to invest in the growth of our oncology business and repayment of debt

Moderna offers $2B in notes to fund cancer business, repay debt

Moderna, Inc. (MRNA) Stock: Slide as Company Upsizes Debt Offering to $2.6 Billion

TLDR Moderna upsizes its convertible notes offering to $2.6 billion as MRNA shares fall. MRNA closes 4.60% lower as Moderna expands its convertible debt financing plan. The notes carry a 0.00% rate and an initial conversion price of about $210.58. Moderna expects up to $2.96 billion in net proceeds if the full option is used. Capped call transactions aim to limit dilution tied to future note conversions. Moderna (MRNA) shares fell after the com…

Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins

Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes for the "flexibility to invest" in growing its oncology business and repay debt ...